ArticleFrontiers in molecular biosciences2025
Screening and characterization of DNA aptamers that modulate prime editing.
Article in Frontiers in molecular biosciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Precise genome editing is a critical focus in gene therapy, and the CRISPR-Cas9 system has become a powerful and versatile tool for this purpose. However, a significant limitation of the CRISPR-Cas9 system is its low homologous recombination rate, which can impede the restoration of normal gene function. To address some of these challenges, advanced gene-editing technologies, such as base editors and prime editors have been developed. Here, we explored whether Cas9-specific single-stranded DNA (ssDNA) aptamers could enhance the PE2 system's functionality. Methods: Systematic evolution of ligands by exponential enrichment (SELEX) was utilized to isolate high-affinity Cas9-specific ssDNA aptamers. Molecular docking simulations were subsequently performed to characterize the binding interactions between these aptamers and the PE2 protein. PE2 editing efficiency was quantitatively assessed using flow cytometry and Sanger sequencing. In bladder cancer cell lines, p53 mutation repair was evaluated by quantitative PCR and Western blot analysis, while cellular responses were examined through proliferation (CCK-8) and apoptosis assays. Results: Molecular docking analysis revealed the interaction sites between SELEX-screened Cas9-specific aptamers and the PE2 protein. The incorporation of these aptamers significantly enhanced PE2 editing efficiency. In bladder cancer cells, the aptamer-PE2 complex effectively restored p53 function, leading to suppressed cellular proliferation and enhanced apoptosis rates. Discussion: Our study demonstrates that Cas9-specific aptamers can effectively enhance prime editing efficiency. This provide new insights into the modulation of prime editing and hold potential for improving its clinical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.